Comparative pharmacokinetics of tyrosine kinase inhibitor, lapatinib, in dogs and cats following single oral administration

Lapatinib is an orally administered tyrosine kinase inhibitor used to treat human epidermal growth factor receptor 2 (HER2) -overexpressing breast cancers in humans. Recently, the potential of lapatinib treatment against canine urothelial carcinoma or feline mammary tumor was investigated. However,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Veterinary Medical Science 2024, Vol.86(3), pp.317-321
Hauptverfasser:	YU, Ting-Wei, YAMAMOTO, Haru, MORITA, Shohei, FUKUSHIMA, Ryuji, ELBADAWY, Mohamed, USUI, Tatsuya, SASAKI, Kazuaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Animals Area Under Curve canine Carcinoma, Transitional Cell - veterinary Cat Diseases Cats Dog Diseases Dogs Dosage ErbB-2 protein feline Female Half-Life human epidermal growth factor receptor 2 inhibitor Humans Lapatinib Mammary gland Oral administration Pharmacokinetics Pharmacology Plasma Protein Kinase Inhibitors Tumors Tyrosine Kinase Inhibitors Urinary Bladder Neoplasms - veterinary Urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!